Hyperion DeFi (NASDAQ:HYPD – Get Free Report) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.
Several other brokerages also recently issued reports on HYPD. Weiss Ratings upgraded Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Chardan Capital lowered their target price on Hyperion DeFi from $8.25 to $7.30 and set a “buy” rating on the stock in a report on Monday, June 8th. Finally, Cantor Fitzgerald raised their price target on Hyperion DeFi from $4.00 to $6.60 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $6.95.
View Our Latest Stock Analysis on HYPD
Hyperion DeFi Stock Up 2.0%
Insider Buying and Selling at Hyperion DeFi
In other news, insider Hyunsu Jung acquired 7,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average price of $3.70 per share, with a total value of $25,900.00. Following the completion of the transaction, the insider directly owned 1,384,676 shares in the company, valued at approximately $5,123,301.20. This represents a 0.51% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.50% of the stock is currently owned by corporate insiders.
Institutional Trading of Hyperion DeFi
Several hedge funds and other institutional investors have recently bought and sold shares of HYPD. Redwood Wealth Management Group LLC raised its holdings in Hyperion DeFi by 2.1% in the 1st quarter. Redwood Wealth Management Group LLC now owns 183,273 shares of the company’s stock valued at $632,000 after acquiring an additional 3,690 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth $73,000. State Street Corp acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth $92,000. Jane Street Group LLC purchased a new stake in shares of Hyperion DeFi in the fourth quarter valued at $493,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Hyperion DeFi in the fourth quarter valued at $663,000. 25.84% of the stock is owned by hedge funds and other institutional investors.
About Hyperion DeFi
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Featured Stories
- Five stocks we like better than Hyperion DeFi
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
